Trial results

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

NCT06635057 on ClinicalTrials.gov · last registry update 2026-05-22

An unusually large phase 4: 166 participants, more than double the 72 typical for the stage. The sponsor logged completion for 15 April 2026. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c). tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P4

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

166

Started

2024-10-11

Primary completion

2026-04-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.